240 related articles for article (PubMed ID: 35017176)
1. Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives.
Youhanna S; Kemas AM; Preiss L; Zhou Y; Shen JX; Cakal SD; Paqualini FS; Goparaju SK; Shafagh RZ; Lind JU; Sellgren CM; Lauschke VM
Pharmacol Rev; 2022 Jan; 74(1):141-206. PubMed ID: 35017176
[TBL] [Abstract][Full Text] [Related]
2. Organotypic and Microphysiological Models of Liver, Gut, and Kidney for Studies of Drug Metabolism, Pharmacokinetics, and Toxicity.
Shen JX; Youhanna S; Zandi Shafagh R; Kele J; Lauschke VM
Chem Res Toxicol; 2020 Jan; 33(1):38-60. PubMed ID: 31576743
[TBL] [Abstract][Full Text] [Related]
3. Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery.
Ekert JE; Deakyne J; Pribul-Allen P; Terry R; Schofield C; Jeong CG; Storey J; Mohamet L; Francis J; Naidoo A; Amador A; Klein JL; Rowan W
SLAS Discov; 2020 Dec; 25(10):1174-1190. PubMed ID: 32495689
[TBL] [Abstract][Full Text] [Related]
4. Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery.
Ewart L; Dehne EM; Fabre K; Gibbs S; Hickman J; Hornberg E; Ingelman-Sundberg M; Jang KJ; Jones DR; Lauschke VM; Marx U; Mettetal JT; Pointon A; Williams D; Zimmermann WH; Newham P
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():65-82. PubMed ID: 29029591
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury.
Zhou Y; Shen JX; Lauschke VM
Front Pharmacol; 2019; 10():1093. PubMed ID: 31616302
[TBL] [Abstract][Full Text] [Related]
6. Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments.
Kemas AM; Zandi Shafagh R; Taebnia N; Michel M; Preiss L; Hofmann U; Lauschke VM
Adv Healthc Mater; 2024 Apr; 13(11):e2303561. PubMed ID: 38053301
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
8. 3D bioprinting for drug discovery and development in pharmaceutics.
Peng W; Datta P; Ayan B; Ozbolat V; Sosnoski D; Ozbolat IT
Acta Biomater; 2017 Jul; 57():26-46. PubMed ID: 28501712
[TBL] [Abstract][Full Text] [Related]
9. Multiorgan Microphysiological Systems for Drug Development: Strategies, Advances, and Challenges.
Wang YI; Carmona C; Hickman JJ; Shuler ML
Adv Healthc Mater; 2018 Jan; 7(2):. PubMed ID: 29205920
[TBL] [Abstract][Full Text] [Related]
10. Reconstituted Human Organ Models as a Translational Tool for Human Organ Response: Definition, Expectations, Cases, and Strategies for Implementation in Drug Discovery and Development.
Tetsuka K; Ohbuchi M; Kawabe T; Goto T; Kiyonaga F; Takama K; Yamazaki S; Fujimori A
Biol Pharm Bull; 2020; 43(3):375-383. PubMed ID: 32115499
[TBL] [Abstract][Full Text] [Related]
11. Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology.
Watson DE; Hunziker R; Wikswo JP
Exp Biol Med (Maywood); 2017 Oct; 242(16):1559-1572. PubMed ID: 29065799
[TBL] [Abstract][Full Text] [Related]
12. Liver microphysiological platforms for drug metabolism applications.
Kulsharova G; Kurmangaliyeva A
Cell Prolif; 2021 Sep; 54(9):e13099. PubMed ID: 34291515
[TBL] [Abstract][Full Text] [Related]
13. Human Organ-on-a-Chip Microphysiological Systems to Model Musculoskeletal Pathologies and Accelerate Therapeutic Discovery.
Ajalik RE; Alenchery RG; Cognetti JS; Zhang VZ; McGrath JL; Miller BL; Awad HA
Front Bioeng Biotechnol; 2022; 10():846230. PubMed ID: 35360391
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation.
Rubiano A; Indapurkar A; Yokosawa R; Miedzik A; Rosenzweig B; Arefin A; Moulin CM; Dame K; Hartman N; Volpe DA; Matta MK; Hughes DJ; Strauss DG; Kostrzewski T; Ribeiro AJS
Clin Transl Sci; 2021 May; 14(3):1049-1061. PubMed ID: 33382907
[TBL] [Abstract][Full Text] [Related]
15. The future of phenotypic drug discovery.
Berg EL
Cell Chem Biol; 2021 Mar; 28(3):424-430. PubMed ID: 33529582
[TBL] [Abstract][Full Text] [Related]
16. The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary.
Baker TK; Van Vleet TR; Mahalingaiah PK; Grandhi TSP; Evers R; Ekert J; Gosset JR; Chacko SA; Kopec AK
Drug Metab Dispos; 2024 Feb; 52(3):198-209. PubMed ID: 38123948
[TBL] [Abstract][Full Text] [Related]
17. Next generation human skin constructs as advanced tools for drug development.
Abaci HE; Guo Z; Doucet Y; Jacków J; Christiano A
Exp Biol Med (Maywood); 2017 Nov; 242(17):1657-1668. PubMed ID: 28592171
[TBL] [Abstract][Full Text] [Related]
18. Current development of integrated web servers for preclinical safety and pharmacokinetics assessments in drug development.
Hsiao Y; Su BH; Tseng YJ
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32770190
[TBL] [Abstract][Full Text] [Related]
19. The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline.
Sutherland ML; Fabre KM; Tagle DA
Stem Cell Res Ther; 2013; 4 Suppl 1(Suppl 1):I1. PubMed ID: 24565163
[TBL] [Abstract][Full Text] [Related]
20. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
